Next Article in Journal
Streptococcus pneumoniae Serotype Distribution and Pneumococcal Conjugate Vaccine Serotype Coverage among Pediatric Patients in East and Southeast Asia, 2000–2014: a Pooled Data Analysis
Previous Article in Journal
Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7
Article Menu

Export Article

Open AccessReview
Vaccines 2016, 4(1), 2; doi:10.3390/vaccines4010002

Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection

1
Laboratory of Molecular Human Retrovirology, Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
2
Department of Microbiology, School of Basic Medical Sciences, Central South University, Changsha 410078, Hunan, China
*
Author to whom correspondence should be addressed.
Academic Editor: Diane M. Harper
Received: 17 November 2015 / Revised: 31 December 2015 / Accepted: 18 January 2016 / Published: 22 January 2016
View Full-Text   |   Download PDF [276 KB, uploaded 22 January 2016]

Abstract

HIV-1 virus-like particles (VLPs) are promising vaccine candidates against HIV-1 infection. They are capable of preserving the native conformation of HIV-1 antigens and priming CD4+ and CD8+ T cell responses efficiently via cross presentation by both major histocompatibility complex (MHC) class I and II molecules. Progress has been achieved in the preclinical research of HIV-1 VLPs as prophylactic vaccines that induce broadly neutralizing antibodies and potent T cell responses. Moreover, the progress in HIV-1 dendritic cells (DC)-based immunotherapy provides us with a new vision for HIV-1 vaccine development. In this review, we describe updates from the past 5 years on the development of HIV-1 VLPs as a vaccine candidate and on the combined use of HIV particles with HIV-1 DC-based immunotherapy as efficient prophylactic and therapeutic vaccination strategies. View Full-Text
Keywords: HIV-1; virus-like paticles (VLPs); vaccine; dendritic cells-based immunotherapy; adjuvants; dendritic cells HIV-1; virus-like paticles (VLPs); vaccine; dendritic cells-based immunotherapy; adjuvants; dendritic cells
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Zhao, C.; Ao, Z.; Yao, X. Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines 2016, 4, 2.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top